Evidence map›Paper›PMID 40167786›Full record

ArticleClinical and experimental medicine2025

Unexpectedly high prevalence of familial Mediterranean fever in Slovakia.

M Jesenak, E Malicherova Jurkova, A Bobcakova, K Hrubiskova, O Petrovicova, L Kapustova, R Kosturiak, T Dallos, A Markocsy

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M JesenakNational Centre for Periodic Fever Syndromes, Department of Pediatrics and Adolescent Medicine, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia.
E Malicherova JurkovaNational Centre for Periodic Fever Syndromes, Department of Pediatrics and Adolescent Medicine, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia.
A BobcakovaNational Centre for Periodic Fever Syndromes, Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia. bobcakova2@uniba.sk.
K HrubiskovaOutpatient Office of Clinical Immunology and Allergology, 5Th Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava, University Hospital Bratislava, Bratislava, Slovakia.
O PetrovicovaNational Centre for Periodic Fever Syndromes, Department of Pediatrics and Adolescent Medicine, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia.
L KapustovaNational Centre for Periodic Fever Syndromes, Department of Pediatrics and Adolescent Medicine, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia.
R KosturiakInstitute of Clinical Immunology and Medical Genetics, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia.
T DallosDepartment of Pediatrics, National Institute of Children's Diseases, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
A MarkocsyNational Centre for Periodic Fever Syndromes, Department of Pediatrics and Adolescent Medicine, Jessenius Faculty of Medicine, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovakia. markocsy2@uniba.sk.ORCID http://orcid.org/0009-0006-4928-7673

Funding

Integrated Infrastructure Operational Program for the project: Systemic Public Research Infrastructure - Biobank for Cancer and Rare Diseases 313011AFG5
6 · The paper itself

Abstract

Familial Mediterranean fever (FMF) is the most common monogenic periodic fever syndrome among all monogenic autoinflammatory diseases. It is characterised by recurrent, self-limited fever attacks of short duration, polyserositis symptoms, and elevated acute-phase reactants. FMF has the highest prevalence in the Eastern Mediterranean region. The first descriptions of FMF cases in Central Europe date back to 2014. The prevalence in the Central European region was previously estimated at 1:465,500 in the paediatric population, with data on adult prevalence lacking. Patients with FMF who fulfilled Eurofever/PRINTO diagnostic criteria were included in the study. Massive parallel sequencing of clinical exome with evaluation of virtual panel for genes associated with inborn errors of immunity and autoinflammatory conditions was used in the vast majority of the patients. Statistical analysis of clinical and laboratory manifestation was performed. The prevalence of FMF in the Slovak population of the present study was 1:48,224 (1:41,348 in children and adolescents), which is significantly higher than expected. The most common variant in our cohort was M694V, present in 52.0% of alleles. Variant K695R was observed in 29.9% which is higher than reported in the other FMF cohorts. Abdominal pain and fever were the most prevalent clinical symptoms, although up to one-third of patients also experienced atypical symptoms such as tonsillitis or cervical lymphadenopathy. This paper provides the first comprehensive analysis of the Slovak National FMF cohort, including epidemiological data, clinical manifestations, and genetic background. Our data could contribute to the general knowledge about FMF characteristics in the underreported regions.

Indexed as

Familial Mediterranean FeverAdolescentAdultChildChild, PreschoolFemaleHumansInfantMalePrevalencePyrinSlovakiaYoung AdultMEFV protein, humanPyrinFamilial Mediterranean feverMEFV genePrevalenceSlovakia

Identifiers

PMID40167786
PMCPMC11961489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.